🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Aldeyra Therapeutics, Inc. ALDX R2KPHARMA

Healthcare · Biotechnology · United States
https://www.aldeyra.com
Company Profile ↓
$1.48
-72.44% 1Y
Mkt Cap$89.28M
P/E-3.29
P/B2.22
52W High$5.89
52W Low$1.24
Book Value$0.70
EPS (TTM)$-0.45

Company Overview

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.37.

Growth & Price Performance

Stock Price Performance

1 Year:-72.44%
6 Months:-69.17%
3 Months:-9.20%
1 Month:-6.92%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 5% of range
$1.24 $5.89
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)40.19 · Neutral
Price Performance
1M-6.92%
3M-9.20%
6M-69.17%
1Y-72.44%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Trading 74.9% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-3.29
Industry PE
25.17
Forward P/E
-6.58
PEG Ratio
-
Book Value
$0.70
Price to Book
2.22
P/S
-
EV/EBITDA
-1.65
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-79.69%
ROE
-51.76%
ROA
-22.22%
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.09
EPS (TTM)
$-0.45

Balance Sheet & Liquidity

Debt/Equity
0.37
Quick Ratio
2.67
Current Ratio
2.72
Debt
$15.51M
Total Assets
$47.54M
Current Assets
$66.27M
Working Capital
$43.97M

Ownership

Promoter Holding
3.60%
Chg in Prom Hold
-
FII / Inst Holding
61.61%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$89.28M
Total Revenue (TTM)
$0
EBITDA
$-28.13M
Free Cash Flow
$-19.60M
Operating Cash Flow
$-25.99M
Shares Outstanding
60.32M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ALDX Aldeyra Therapeutics, Inc. R2KPHARMA 1.48 -3.29 $89.28M 0.00% -79.69% -51.76% - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ----------------------------------00000-
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses ----------------------------------10.43M10.17M8.00M6.67M3.55M-
Operating Income -1.17M-1.24M-1.65M-1.97M-2.11M-2.20M-3.34M-4.97M-4.30M-4.78M-5.10M-5.33M-5.02M-8.49M-9.17M-10.95M-17.43M-13.73M-19.02M-9.64M-7.11M-8.39M-10.83M-14.54M-15.44M-16.48M-17.71M-14.78M-16.80M-10.34M-9.55M-9.39M-18.01M--10.43M-10.17M-8.00M-6.67M-3.55M-5.85M
EBITDA -----------------------------------9.39M-9.23M-7.15M-5.92M-2.92M-
Interest Expense ----------------------------------483.53K470.62K475.90K475.26K468.68K-
Pretax Income -----------------------------------9.93M-9.77M-7.69M-6.46M-3.45M-
Tax Provision ----------------------------------------
Net Income 9.31M401.77K-1.14M-2.01M-2.14M-2.23M-3.37M-4.97M-4.30M-4.78M-5.09M-5.31M-4.99M-8.40M-9.05M-10.81M-15.62M-13.33M-18.72M-9.87M-7.52M-8.87M-11.29M-14.94M-15.79M-16.79M-17.78M-14.55M-15.62M-8.99M-8.19M-8.08M-16.85M--9.93M-9.77M-7.69M-6.46M-3.45M-5.45M
Diluted EPS -9.81-4.04-1.56-0.36-0.32-0.27-0.35-0.51----------------0.28-0.27-0.29-0.30-0.25-0.27-0.15-0.14-0.14-0.28-0.25-0.17-0.16-0.13--0.06-0.09
R&D Expense 666.04K444.28K663.91K1.20M1.14M1.25M2.08M3.51M2.83M3.38M3.37M3.85M3.54M6.60M6.79M7.88M7.85M10.66M16.22M6.63M4.89M6.13M7.73M11.47M12.89M12.23M14.57M11.54M11.24M6.96M6.96M6.18M14.97M12.44M7.42M8.51M5.43M-2.41M3.48M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue ---------0000
Cost of Revenue -------------
Gross Profit -------------
Operating Expenses ---------62.68M42.79M60.12M35.27M
Operating Income -3.68M-7.27M-11.99M-18.70M-22.49M-39.70M-63.07M-36.42M--62.68M-42.79M-60.12M-35.27M
EBITDA ----------60.07M-35.21M-53.68M-31.69M
Interest Expense ---------1.69M2.07M1.93M1.91M
Pretax Income ----------62.02M-37.54M-55.85M-33.85M
Tax Provision --------0----
Net Income 13.06M-5.19M-12.09M-18.70M-22.34M-38.89M-60.83M-37.55M--62.02M-37.54M-55.85M-33.85M
Diluted EPS -17.61-3.09-1.40-------1.06-0.64-0.94-0.56
R&D Expense 1.54M3.71M7.57M13.18M16.30M29.82M44.35M24.68M44.94M47.31M29.46M48.22M25.66M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Jan 2016Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -3.74M8.79M28.20M-25.19M44.17M95.09M75.52M83.35M-181.29M148.33M104.61M72.06M
Current Assets -----------181.02M147.81M104.07M71.78M
Cash & Equivalents 1.22M3.26M8.53M14.65M14.65M12.02M20.02M47.36M44.43M77.86M-144.42M142.82M54.53M70.04M
Inventory ---------------
Receivables ----------28.77K3.24M0--
Total Liabilities -5.65M2.50M3.33M-3.54M4.57M8.47M27.44M23.84M-30.28M28.53M33.60M27.81M
Current Liabilities -605.01K1.33M2.12M-2.30M3.35M8.47M12.91M12.41M-15.36M22.26M18.60M27.81M
Long Term Debt -1.13M1.18M1.21M-1.24M1.22M-14.53M11.43M15.50M14.92M-15.00M-
Total Debt -----------16.08M15.66M15.30M15.53M
Total Equity -54.38M-40.22M6.28M24.88M24.88M21.65M39.60M86.62M48.08M59.51M-151.01M119.80M71.00M44.25M
Shares Outstanding -----------58.56M59.20M59.65M60.16M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ----19.22M-29.86M-44.98M-37.49M--56.64M-30.33M-43.21M-33.35M
Investing Cash Flow ----10.20M-23.34M18.48M29.02M--29.95M30.00M-44.92M47.74M
Financing Cash Flow ---37.43M80.53M23.58M41.90M-1.22M-1.27M-171.42K1.12M
Capital Expenditure -14.06K-86.12K-11.81K-24.76K-262.97K-9.53K--7.81K-16.32K---
Free Cash Flow ----19.25M-30.12M-44.99M---56.65M-30.33M-43.21M-33.35M
Net Change in Cash ---------85.37M-1.60M-88.30M15.51M

Ratios (Annual)

Figures in %.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------
Operating Margin % -------------
Net Margin % -------------
ROE % -32.5%-82.5%-48.6%-86.4%-56.4%-44.9%-126.5%-63.1%--41.1%-31.3%-78.7%-76.5%
ROCE % -117.1%-97.5%-46.0%-81.7%-55.1%-45.8%-100.7%-51.3%--37.8%-33.9%-69.9%-79.7%

Shareholding Pattern

Insiders
3.60%
Institutions
61.61%
Public Float
63.91%

Top Institutional Holders

#Holder% HeldSharesValue
1 Knoll Capital Management, LLC 9.08% 5.48M $8.13M
2 AQR Capital Management, LLC 6.22% 3.75M $5.57M
3 Kingdon Capital Management LLC 4.40% 2.65M $3.94M
4 Vanguard Capital Management LLC 3.92% 2.36M $3.51M
5 Shaw D.E. & Co., Inc. 3.22% 1.94M $2.88M
6 Marshall Wace LLP 2.50% 1.51M $2.24M
7 683 Capital Management LLC 2.40% 1.45M $2.15M
8 Jane Street Group, LLC 2.28% 1.38M $2.04M
9 Blackrock Inc. 2.08% 1.26M $1.87M
10 Qube Research & Technologies Ltd 1.87% 1.13M $1.68M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ALDX

Yahoo Finance ue, 07 Jul 2026

Levicept Appoints Darlene Deptula-Hicks as CFO

Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for OsteoarthritisSANDWICH, United Kingdom, July 07, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focus…

Yahoo Finance Wed, 10 Jun 2026

CEO, President & Director of Aldeyra Therapeutics Picks Up 18% More Stock

Investors who take an interest in Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) should definitely note that the CEO...

Yahoo Finance Wed, 10 Jun 2026

Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors

LEXINGTON, Mass., June 10, 2026--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced the appoint…

Yahoo Finance Fri, 05 Jun 2026

Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment

Aldeyra Therapeutics (NASDAQ:ALDX) Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap, following a third complete response letter tie…

Yahoo Finance ue, 02 Jun 2026

Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

LEXINGTON, Mass., June 02, 2026--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C…

Yahoo Finance Fri, 15 May 2026

3 Stocks That May Be Undervalued According To Analysts In May 2026

Over the last 7 days, the United States market has risen by 1.1%, contributing to a remarkable 27% climb over the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, identifying stocks that may be unde…

ALDX — Frequently Asked Questions

What is the current share price of Aldeyra Therapeutics, Inc. (ALDX)?

As of 2026-09-07 16:24 PDT, Aldeyra Therapeutics, Inc. (ALDX) trades at $1.48 on NasdaqCM. Its 52-week range is $1.24 to $5.89.

What is the market capitalisation of ALDX?

Aldeyra Therapeutics, Inc. (ALDX) has a market capitalisation of $89.28M on NasdaqCM.

What is the P/E ratio of ALDX?

ALDX trades at a trailing price-to-earnings (P/E) ratio of -3.29. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.22.

What is the return on equity (ROE) of ALDX?

ALDX has a return on equity (ROE) of -51.76%. Its return on capital employed (ROCE) is -79.69%.

Is ALDX a good stock to buy?

This page provides a data-driven analysis of Aldeyra Therapeutics, Inc. (ALDX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space